SCHEMBL2635663

SCHEMBL2635663

O=C(O)c1cc(O)c2c(Cl)cc(Cl)cc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 2/20 0.50
HCAR1 Q9BXC0 1/20 0.48
TTR P02766 2/20 0.47
HPGD P15428 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
KDM4E B2RXH2 2/20 0.45
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
MAPT P10636 2/20 0.45
CA4 P22748 2/20 0.45
CA6 P23280 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
CA3 P07451 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14743925 0.81 TPMT (0.48) TPMTHCAR1TTRHPGDTDP1
SCHEMBL12193739 0.81 MEN1 (0.59) TPMTHCAR1TTRHPGDTDP1
SCHEMBL29914372 0.80 CA12 (0.61) TPMTTTRHPGDTDP1KDM4E
SCHEMBL686591 0.80 CA12 (0.61) TPMTTTRHPGDTDP1KDM4E
SCHEMBL2635582 0.80 LMNA (0.51) TPMTHPGDTDP1KDM4ECA12
SCHEMBL11677963 0.78 TTR (0.60) TPMTHCAR1TTRHPGDTDP1
SCHEMBL14744302 0.74 ACLY (0.46) TPMTHPGDMAPTALDH1A1LMNA
SCHEMBL2635965 0.73 TDP1 (0.51) TPMTTDP1KDM4EMAPTMEN1
SCHEMBL342924 0.72 CA12 (0.50) TPMTTTRHPGDTDP1KDM4E
SCHEMBL342923 0.72 CA12 (0.50) TPMTTTRHPGDTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 TPMT 706/4885HCAR1 890/4885TTR 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.